Allston LabWorks Lands Rebranded Biotech For First Lab Lease

Why It Matters

The deal validates demand for purpose‑built biotech space in Boston’s emerging Allston corridor and signals confidence in Terrestrial’s growth trajectory after a sizable funding round. It also demonstrates King Street’s ability to attract anchor life‑science tenants, bolstering the mixed‑use development’s ecosystem.

Key Takeaways

• Terrestrial Bio signs 42,000 SF lease at Allston LabWorks.
• Deal marks first lab tenant for King Street’s Allston project.
• Terrestrial raises $50 million Series C and rebrands from Vaxess.
• Allston LabWorks development cost $915 million, 534k SF labs.
• Project includes retail, housing, and nonprofit life‑science training.

Pulse Analysis

Boston’s biotech landscape continues to expand beyond traditional hubs like Cambridge, with developers targeting Allston’s western corridor to meet rising demand for flexible, purpose‑built laboratory space. Mixed‑use projects such as King Street’s Allston LabWorks combine 534,000 square feet of labs with retail and residential units, creating a live‑work ecosystem that appeals to both established firms and early‑stage startups. By integrating training nonprofits and community amenities, the campus aims to foster a pipeline of talent and innovation, positioning Allston as a complementary node in the region’s life‑science cluster.

Terrestrial Bio’s 42,000 square‑foot lease marks a strategic escalation for the company, which recently secured $50 million in Series C capital and rebranded from Vaxess Technologies. The funding will accelerate commercialization of its pharmaceutical patch platform, while the new Allston headquarters consolidates research, development, and manufacturing under one roof. Maintaining a 10,000 square‑foot foothold in Woburn ensures operational continuity, but the larger Boston footprint offers proximity to academic partners, talent pools, and a vibrant investor community, enhancing the firm’s growth prospects.

For King Street Properties, landing an anchor biotech tenant validates the mixed‑use model and paves the way for future phases, including a planned 90,000 square‑foot lab project next door. The successful lease may attract additional life‑science firms seeking modern facilities, driving higher occupancy rates and rental premiums. As Boston’s biotech leasing market tightens, developers that blend lab capacity with retail and housing are likely to capture premium demand, reinforcing the city’s status as a premier destination for pharmaceutical innovation.